Glycosmedia Weekly Diabetes News - 03/04/2016

Diagnosis and Management of Diabetes

Synopsis of the 2016 American Diabetes Association Standards of Medical Care in Diabetes (Annals of Internal Medicine)

Insulin pump use compared with intravenous insulin during labour and delivery: the INSPIRED observational cohort study

This study demonstrates that the continuation of CSII therapy during labour and delivery appears safe and efficacious. Moreover, women who choose to continue CSII have better glucose control during delivery than those who switch to IV insulin, suggesting that it should be standard practice to allow women the option of continuing CSII during labour and delivery (Diabetic Medicine)

Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes. The DUAL V Randomized Clinical Trial

Among patients with uncontrolled type 2 diabetes taking glargine and metformin, treatment with degludec/liraglutide compared with up-titration of glargine resulted in noninferior HbA1c levels, with secondary analyses indicating greater HbA1c level reduction after 26 weeks of treatment. Further studies are needed to assess longer-term efficacy and safety (JAMA)

Eylea outperforms Avastin for diabetic macular edema with moderate or worse vision loss

NIH-funded clinical trial shows Eylea, Avastin, and Lucentis perform similarly when vision loss is mild (National Institutes of Health)

Diabetic Microangiopathy Is an Independent Predictor of Incident Diabetic Foot Ulcer

The presence of DR and Alb significantly increases the risk of diabetic foot ulcer development (Journal of Diabetes Research)

Effects of TZD Use and Discontinuation on Fracture Rates in ACCORD Bone Study

TZD use was associated with increased non-spine fractures in women, but not men, with type 2 diabetes. When women discontinued TZD use, the fracture effects were attenuated (Journal of Clinical Endocrinology & Metabolism)

Absence of Coronary Artery Calcium Identifies Asymptomatic Diabetic Individuals at Low Near-Term But Not Long-Term Risk of Mortality

CAC=0 is associated with a favorable 5-year prognosis for asymptomatic diabetic and nondiabetic individuals. After 5 years, the risk of mortality increases significantly for diabetic individuals even in the presence of a baseline CAC=0 (Circulation: Cardiovascular Imaging)

EMA confirms recommendations to minimise ketoacidosis risk with SGLT2 inhibitors for diabetes

Healthcare professionals should be aware of possible atypical cases (European Medicines Agency)